Parcours professionnel
- Membre de l’Association des Neuro-oncologues d’Expression Française (ANOCEF)
- 2022-2025 – Chef de Clinique des universités – Assistant hospitalier – Neuro-oncologie (Hospices Civils de Lyon et Université Claude Bernard Lyon 1)
- 2022 – Diplôme d’études spécialisés complémentaires en Cancérologie – Université Claude Bernard Lyon 1
- 2021-2022 – Assistant Spécialiste – Neuro-oncologie (Hospices Civils de Lyon)
- 2021 – Diplôme d’Etat de Docteur en médecine et Diplôme d’études spécialisées en Neurologie – Université Claude Bernard Lyon 1
- 2020 – Diplôme inter Universitaire – Neuro-oncologie – Université Claude Bernard Lyon 1
- 2020 – Master 2 Biologie du Cancer – Université Claude Bernard Lyon 1
- 2016-2021 – Internat de Neurologie et Neuro-oncologie (Hospices Civils de Lyon, Centre Léon Bérard, Assistance Publique-Hôpitaux de Paris La Pitié-Salpêtrière)
- 2016 – Admission à l’ECN (rang 400), spécialité : Neurologie – Université Claude Bernard Lyon 1
- 2013 – Master 1 Biologie et technologie de la santé – Université Jacques Lisfranc Saint-Etienne
- 2011 – Admission PACES (rang 4) – Université Jacques Lisfranc Saint-Etienne
- 2010 – Baccalauréat Section Scientifique Mention Bien – Lycée Champagnat (Saint-Symphorien-sur-Coise)
Publications
- Seyve A, Lozano-Sanchez F, Thomas A, Mathon B, Tran S, Mokhtari K, Giry M, Marie Y, Capelle L, Peyre M, Carpentier A, Feuvret L, Sanson M, Hoang-Xuan K, Honnorat J, Delattre JY, Ducray F, Idbaih A. Initial surgical resection and long time to occurrence from initial diagnosis are independent prognostic factors in resected recurrent IDH wild-type glioblastoma. Clin Neurol Neurosurg. 2020 Sep;196:106006. doi: 10.1016/j.clineuro.2020.106006. Epub 2020 Jun 8. PMID: 32554237.
- Seyve A, Dehais C, Chinot O, Djelad A, Cohen-Moyal E, Bronnimann C, Gourmelon C, Emery E, Colin P, Boone M, Vauléon E, Langlois O, di Stefano AL, Seizeur R, Ghiringhelli F, D'Hombres A, Feuvret L, Guyotat J, Capelle L, Carpentier C, Garnier L, Honnorat J, Meyronet D, Mokhtari K, Figarella-Branger D, Ducray F. Incidence and characteristics of pseudoprogression in IDH-mutant high-grade gliomas: A POLA network study. Neuro Oncol. 2023 Mar 14;25(3):495-507. doi: 10.1093/neuonc/noac194. PMID: 35953421; PMCID: PMC10013645.
- Durand S, Bruelle M, Bourdelais F, Bennychen B, Blin-Gonthier J, Isaac C, Huyghe A, Martel S, Seyve A, Vanbelle C, Adrait A, Couté Y, Meyronet D, Catez F, Diaz JJ, Lavial F, Ricci EP, Ducray F, Gabut M. RSL24D1 sustains steady-state ribosome biogenesis and pluripotency translational programs in embryonic stem cells. Nat Commun. 2023 Jan 23;14(1):356. doi: 10.1038/s41467-023-36037-7. PMID: 36690642; PMCID: PMC9870888.
- Esparragosa Vazquez I, Ndiaye M, Di Stefano AL, Younan N, Larrieu-Ciron D, Seyve A, Picart T, Meyronet D, Boutet C, Vassal F, Carpentier C, Figarella-Branger D, Dehais C, Forest F, Rivoirard R, Ducray F; POLA network. T2-Fluid-attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone. Eur J Neurol. 2023 Sep;30(9):2879-2883. doi: 10.1111/ene.15873. Epub 2023 May 31. PMID: 37204066.
- Farina A, Escalere M, Dion M, Moussy M, Pegat A, Villagrán-García M, Devic P, Lamiral A, Seyve A, Aure K, Wang A, Gorza L, Streichenberger N, Maisonobe T, Honnorat J, Birzu C, Psimaras D, Weisenburger-Lile D, Joubert B. Mononeuritis multiplex following immune checkpoint inhibitors in malignant pleural mesothelioma. Front Neurol. 2024 Jan 25;15:1338899. doi: 10.3389/fneur.2024.1338899. PMID: 38333608; PMCID: PMC10850347.
- Guidara S, Seyve A, Poncet D, Leonce C, Bringuier PP, McLeer A, Sturm D, Cartalat S, Picart T, Ferrari A, Hench J, Frank S, Meyronet D, Ducray F, Barritault M. Characteristics of H3K27M-mutant diffuse gliomas with a non-midline location. J Neurooncol. 2024 Sep;169(2):391-398. doi: 10.1007/s11060-024-04733-z. Epub 2024 Jun 27. PMID: 38937309.
- Figarella-Branger D, Colin C, Mokhtari K, Uro-Coste E, Idbaih A, Appay R, Tabouret E, Touat M, Seyve A, Carpentier C, Dehais C, Ducray F; POLA network. Reappraisal of prognostic factors in CNS WHO grade 3 oligodendrogliomas IDH-mutant and 1p/19q co-deleted: Lessons from the French POLA cohort. Neuro Oncol. 2025 Mar 7;27(3):755-766. doi: 10.1093/neuonc/noae221. PMID: 39432559; PMCID: PMC11889709.
- Gkasdaris G, Berthiller J, Guyotat J, Jouanneau E, Gallet C, Meyronet D, Thomas L, Cartalat S, Seyve A, Honnorat J, Ducray F, Picart T. Is Carmustine Wafer Implantation in Progressive High-Grade Gliomas a Relevant Therapeutic Option? Complication Rate, Predictors of Complications and Onco-Functional Outcomes in a Series of 53 Cases. Cancers (Basel). 2024 Oct 12;16(20):3465. doi: 10.3390/cancers16203465. PMID: 39456559; PMCID: PMC11506748.
- PFMG2025 contributors. PFMG2025-integrating genomic medicine into the national healthcare system in France. Lancet Reg Health Eur. 2025 Jan 6;50:101183. doi: 10.1016/j.lanepe.2024.101183. PMID: 40093400; PMCID: PMC11910791.
- Seyve A, Ducray F. Open questions on vorasidenib. Curr Opin Oncol. 2025 Nov 1;37(6):589-594. doi: 10.1097/CCO.0000000000001193. Epub 2025 Sep 12. PMID: 41029964.
- Tommasino E, Ducray F, Seyve A, Picard T, Martin A, Gamondes D, Delevaux EJ, Hermier M, Berthezene Y, Bani-Sadr A. CMRO2 (DSC-PW) perfusion parameter helps to distinguish between progression and pseudoprogression in patients with glioblastoma. Radiol Med. 2025 Oct 3. doi: 10.1007/s11547-025-02103-x. Epub ahead of print. PMID: 41042283.
